跳至主要内容
临床试验/NCT00527592
NCT00527592已完成4 期

A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Alcon Research0 个研究点目标入组 54 人开始时间: 2007年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
54
主要终点
Comfort Immediately After Dosing

研究概览

简要总结

The purpose of this study is to compare the comfort of Travatan Z in one eye and Xalatan in the opposite eye in patients with primary open-angle glaucoma or ocular hypertension.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age or older.
  • Clinical diagnosis of ocular hypertension, primary open-angle, pigment dispersion, or exfoliation glaucoma in both eyes.
  • Best corrected visual acuity of 20/200 Snellen or better in each eye.
  • Intraocular pressure within protocol-specified range.
  • Other protocol-defined inclusion criteria may apply.

排除标准

  • Any abnormality preventing reliable applanation tonometry in the study eye(s).
  • Any eye conditions or procedures as specified in protocol.
  • Progressive retinal or optic nerve disease from any cause.
  • Use of contact lenses in the study eye(s).
  • Other protocol-defined exclusion criteria may apply.

研究组 & 干预措施

Travoprost

Experimental

Travoprost assigned to one eye, with latanoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.

干预措施: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) (Drug)

Latanoprost

Active Comparator

Latanoprost assigned to one eye, with travoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.

干预措施: Latanoprost ophthalmic solution 0.005% (XALATAN®) (Drug)

结局指标

主要结局

Comfort Immediately After Dosing

时间窗: 5 seconds

Comfort was assessed by the patient and recorded on a scale of 0 to 100, with 0 = perfect comfort and 100 = worse discomfort imaginable.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

A Single Dose Comfort Comparison of Travatan Z in... | 临床试验